Skip to main content

Table 1 Clinicopathological characteristics

From: Comparison of short-term outcomes between transthoracic and robot-assisted transmediastinal radical surgery for esophageal cancer: a prospective study

  TME (n = 25) TTE (n = 35) p value*
Median age (range) 66 (43–78) 66 (51–82) 0.96
Sex (M/F) 23/2 28/7 0.28
Median BMI (range) 22.4 (17.9–28.6) 22.2 (17.5–29.7) 0.55
ECOG-PS (0/1) 9/16 10/25 0.58
Brinkman Index (0/ 1–600/ 601–1200/ 1201-) 7/10/5/3 7/12/13/3 0.55
Location (Proximal/Middle/Distal/EGJ) 2/18/4/1 2/19/8/6 0.35
Anastomosis site (Cervical/Intrathoracic) 25/0 7/28 <.0001*
Number of three-field lymphadenectomies (%) 22 (88.0%) 23 (65.7%) 0.07
Clinical classification
 cT Status (0/1/2/3) 0/17/8/0 2/13/10/10 0.0043*
 cN Status (0/1/2) 20/5/0 28/6/1 1.00
Pathological classification
 pT Status (0/1/2/3) 0/19/3/3 1/16/2/16 0.01*
 pN Status (0/1/2/3) 13/6/5/1 16/12/5/2 0.16
 pStage (0/IA/IB/IIA/IIB/IIIA/IIIB/IIIC) 0/10/2/1/5/6/0/1 1/11/1/3/5/8/5/1 0.52
 Resection status (R0/R1/R2) 25/0/0 34/1/0 1.00
 Histological type (SCC/AC/Other) 24/0/1 31/3/1 0.38
  Number of cases (%) p value
Neoadjuvant chemotherapy: n (%) 2 (8.0%) 11 (31.4%) 0.054
Adjuvant chemotherapy: n (%) 9 (36.0%) 11 (31.4%) 0.78
  1. *Fisher’s exact test. AC, adenocarcinoma; BMI, body mass index; EGJ, esophagogastric junction; SCC, squamous cell carcinoma; TME, transmediastinal esophagectomy; TTE, transthoracic esophagectomy